Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck

Nicole DeFeudis

Editor

Conner Mitchell

As Pfizer and BioNTech’s vaccine delivery runs behind schedule in the EU, Merck KGaA is aiming to boost production by accelerating its supply of custom …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck

Nicole DeFeudis

Editor

Conner Mitchell

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Compounded weight loss drugs have resulted in misdosing, hospitalizations, FDA warns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Mer­ck KGaA ex­pands its deal with Pfiz­er/BioN­Tech with an eye on a key vac­cine man­u­fac­tur­ing bot­tle­neck

Editor

Sign up to read this article for free.

Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck